DexCom: Investors Discounting Long CGM Growth Runway
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...
Medscape4d
CGM Cuts Hospitalization in T2D, Even in Non-Insulin Treated
Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...
medtechdive4d
Senseonics receives FDA clearance for one-year CGM
The continuous glucose monitor (CGM), called Eversense 365 ... In addition to the longer wear time, the new sensor requires less frequent calibration using fingersticks; calibration is only required ...
FierceBiotech5d
FDA clears Senseonics' 365-day Eversense CGM implant
After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...